BioAge Labs, Inc. (BIOA)
Investors who lost money on BioAge Labs, Inc. should contact Levi & Korsinsky about an ongoing investigation - BIOA
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
Shareholder Rights Advocates at Levi & Korsinsky Investigate BioAge Labs, Inc. (BIOA) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / January 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
Levi & Korsinsky Announces an Investigation on Behalf of BioAge Labs, Inc. (BIOA) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioAge Labs, Inc. - BIOA
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ:BIOA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into BioAge Labs Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / December 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures – Hagens Berman
BIOA Investors with Significant Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / December 30, 2024 / On December 9, 2024, just months after conducting an initial public offering in September 2024, BioAge Labs, Inc. (NASDAQ:BIOA) made the startling announcement that it was discontinuing a Phase 2 study for its lead product, azelaprag, intended to treat metabolic diseases such as obesity. Hagens Berman has opened an investigation and urges investors in BioAge who purchased shares in the company's IPO or on the open market and suffered substantial losses to submit your losses now.
BIOA STOCK REPORT: BioAge Labs is Under Investigation after the Stock Dropped 76% – Contact BFA Law if You have Losses on Your Investment
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ:BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting Click Here
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioAge Labs, Inc. - BIOA
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ:BIOA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
BioAge Labs, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / December 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into BioAge Labs Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / December 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioAge Labs, Inc. - BIOA
Pomerantz LLP is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ:BIOA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
BioAge Labs, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / December 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
